Human Immunodeficiency Virus (HIV) is a serious infection that attacks the body’s immune system. Early detection and diagnosis are crucial for managing the disease and preventing its progression to Acquired Immunodeficiency Syndrome (AIDS). This article explores the symptoms of HIV and the methods used for its diagnosis. Symptoms of HIV HIV symptoms vary depending on […]
In a significant move to enhance its immunology offerings, Johnson & Johnson (NYSE: JNJ) has announced a definitive agreement to acquire a wholly-owned subsidiary of Numab Therapeutics, gaining global rights to an investigational bispecific antibody, NM26. The deal, valued at approximately $1.25 billion, is poised to transform treatment paradigms in atopic dermatitis (AD) and potentially […]
Eli Lilly and Company (Lilly) has finalized its acquisition of DICE Therapeutics, Inc. (NASDAQ: DICE) for $2.4 billion, bolstering its immunology portfolio with the inclusion of the latter’s innovative oral therapeutic candidates. This acquisition, made in an all-cash transaction, will incorporate DICE Therapeutics’ breakthrough DELSCAPE technology platform, designed for developing advanced oral therapeutic candidates. Specifically, […]
AbbVie and Scripps Research institute’s division Calibr have announced a broadened strategic collaboration targeted at developing preclinical and early-stage clinical assets across a host of therapeutic areas such as immunology, oncology, and neuroscience. The extended partnership which aligns with AbbVie’s core areas of interest builds upon the company’s 2019 partnership with Scripps Research. Thomas Hudson, […]
Acelyrin has acquired ValenzaBio, a privately held clinical-stage biopharmaceutical company, in an all-stock deal. With the acquisition of ValenzaBio, the US- based late-stage clinical biopharma company, anticipates to add multiple clinical and pre-clinical development programs to its immunology pipeline, including a potentially differentiated therapeutic for the treatment of thyroid eye disease. Acelyrin’s immunology portfolio is […]
Spanish pharma company Grifols has agreed to acquire Tiancheng (Germany) Pharmaceutical, which holds nearly 90% stake of German publicly listed healthcare company Biotest. The deal values 100% of Biotest at €1.6 billion. Grifols will acquire Tiancheng (Germany) Pharmaceutical from Hong Kong-registered Tiancheng International Investment. The consideration is made up of €773 million and a loan […]
Alexion Pharmaceuticals has secured a significant milestone with the FDA granting priority review for its C5 complement inhibitor, SOLIRIS (eculizumab), as a treatment for neuromyelitis optica spectrum disorder (NMOSD) in patients who test positive for anti-aquaporin-4 (AQP4) autoantibodies. This critical approval comes as part of a supplemental Biologics License Application (sBLA), which has been accepted […]
German pharmaceutical giant Merck is set to invest $70 million to expand its EMD Serono research and development (R&D) facility in Billerica, Massachusetts. This major investment will support the company’s efforts in advancing drug discoveries, specifically in oncology, immuno-oncology, and immunology. The expansion, which includes the construction of a new 145,000 square-foot building, will help […]